Compare Citius Pharmaceuticals Inc (CTXR) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Wipro Limited — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Wipro Limited trades at $1.69 (market cap $16.22B). The key difference: Wipro Limited is far larger — about 1190.9× Citius Pharmaceuticals Inc's market cap, and Wipro Limited pays a 5.19% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Wipro Limited for 41 Days on average.
| CTXR | WIT | |
|---|---|---|
Market Cap | $13.62M | $16.22B |
Volume | 132,438 | 9,028,667 |
Sector | Health | Technology |
52-Week High | $1.82 | $3.06 |
52-Week Low | $0.48 | $1.61 |
Typical Hold Time | 16 Days | 41 Days |
Enterprise Value | $3.79M | $14.33B |
Dividend Yield | — | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Wipro (WIT) trades at $1.67, down 0.6% with bearish technical signals despite recent gap-up momentum. The company maintains solid fundamentals with $890.88B revenue and 13.92% net margin in 2025, though recent quarters show earnings misses. Analyst sentiment is mixed with only 19% buy ratings, while AI partnerships and productivity gains provide growth catalysts.
Wipro presents a cautious opportunity with reasonable valuation (P/E 12.78) but faces execution risks amid competitive IT services market. The stock's outlook depends on reversing recent earnings misses while leveraging AI initiatives that have already boosted productivity equivalent to 20,000 workers according to company reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
